Conversely, Early Breast Cancer Trialists’ Collaborative Group reported that adding adjuvant polychemotherapy to tamoxifen was associated with 7.6% of 5-year survival gain in patients aged < 50 years with ER-positive tumors [21]. This evidence concerns the gene ESR1 and breast carcinoma.